Switch to
More onapp

How to use scorecard? Learn more

Genomic Valley Biotech Ltd

GVBL
Health CareBiotechnology
SmallcapWith a market cap of ₹10 cr, stock is ranked 4,116
High RiskStock is 4.60x as volatile as Nifty
32.500.36 (-1.10%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CareBiotechnology
SmallcapWith a market cap of ₹10 cr, stock is ranked 4,116
High RiskStock is 4.60x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
9.38
PB RatioPB Ratio
2.85
Dividend YieldDiv. Yield
Sector PESector PE
51.73
Sector PBSector PB
5.88
Sector Div YldSctr Div Yld
0.57%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Genomic Valley Biotech Ltd is conducting research in the field of Biotechnology (Plant & Animal) and also to undertake commercial production of Plant Tissue Cultured Plants of different species to feed the genetically improved plant market

Financial TrendFinancial statements 

20202021202220230.860.210.572.760.29-0.57-0.010.65
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 2.14%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Company Update 
Announced OnApr 21, 2024

Genomic Valley Biotech Ltd - 539206 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | Download

Genomic Valley Biotech Ltd - 539206 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | Download

See all events